Oragenics CFO granted 55,900 stock options

Oragenics Inc reported that its Chief Financial Officer, John Spencer, received a grant of stock options.

Rhea-AI Filing Summary

Oragenics Inc reported that its Chief Financial Officer, John Spencer, received a grant of stock options. The award covers 55,900 options to buy Oragenics common stock at an exercise price of $0.59 per share under the company’s 2021 Equity Incentive Plan.

According to the terms, one fifth of the options vest on the grant date, with the remaining options vesting in equal annual installments on the first through fourth anniversaries of the grant date, contingent on continued service. Following this grant, Spencer holds 55,900 derivative securities related to this award, which expire on July 1, 2036. The filing shows no open-market purchases or sales of common stock.

Insider Trade Summary

Grant/Award: 55,900 shares

Grant/Award 1 txn

Insider Spencer John

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	55,900	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 55,900 contracts (Direct)

Footnotes (1)

1. F1. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.

Key Figures

Option grant size: 55,900 options Exercise price: $0.59 per share Expiration date: July 1, 2036 +2 more

5 metrics

Option grant size 55,900 options Employee stock option award to CFO

Exercise price $0.59 per share Stock option exercise price for common stock

Expiration date July 1, 2036 Option expiration for CFO grant

Initial vesting portion 20% of options One fifth vest on the grant date

Post-grant derivative holdings 55,900 derivative securities Total options held following transaction

Key Terms

Employee Stock Option (right to buy), 2021 Equity Incentive Plan, vesting, exercise price

4 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

2021 Equity Incentive Plan financial

"under the Company's 2021 Equity Incentive Plan, as amended"

vesting financial

"one fifth of the options vest on the grant date and the remainder of the options subsequently vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"The option exercise price is the Company's closing price on the date of grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oragenics (OGEN) disclose for its CFO?

Oragenics disclosed that Chief Financial Officer John Spencer received a grant of 55,900 employee stock options. These options give him the right to buy common stock at a fixed exercise price of $0.59 per share under the 2021 Equity Incentive Plan.

How many stock options were granted to the Oragenics CFO in this Form 4?

The Form 4 reports a grant of 55,900 employee stock options to the Oragenics CFO. Each option relates to one share of common stock, creating a potential future right to purchase 55,900 shares if the options are exercised.

What is the exercise price and expiration date of the Oragenics CFO options?

The options granted to the Oragenics CFO carry an exercise price of $0.59 per share and expire on July 1, 2036. This means they can be exercised at $0.59 any time before that expiration date, subject to vesting.

How do the Oragenics CFO stock options vest according to the filing?

The filing states one fifth of the options vest on the grant date, with the remainder vesting in equal annual installments on the first, second, third, and fourth anniversaries. Vesting requires the CFO to continue performing services through each vesting date.

Did the Oragenics CFO buy or sell any common shares in this Form 4?

No open-market purchases or sales of common stock are reported. The filing only shows an acquisition of derivative securities via an employee stock option grant, classified as a grant, award, or other acquisition transaction under code A.

What is the total number of derivative securities the Oragenics CFO holds after this grant?

After this transaction, the Form 4 reports that the Oragenics CFO holds 55,900 derivative securities related to this option award. This total matches the number of options granted in the transaction, indicating the full award is reflected as of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 05:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spencer John

(Last) (First) (Middle)

9015 TOWN CENTER PARKWAY, SUITE 143

(Street)

LAKEWOOD RANCH FLORIDA 34202

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$0.59	07/01/2026		A		55,900		(1)	07/01/2036	Common Stock	55,900	$0	55,900	D

Explanation of Responses:

1. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended. One fifth of the options vest on the grant date and the remainder of the options subsequently vest in equal annual installments over the first, second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the Company's closing price on the date of grant.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Reporting Person	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)